Factor V Leiden mutation and PAI-1 gene 4G/5G genotype in thrombotic patients with Behcet's disease

2003 ◽  
Vol 14 (2) ◽  
pp. 121-124 ◽  
Author(s):  
Aytemiz Gurgey ◽  
Gunay Balta ◽  
Ayse Boyvat
2004 ◽  
Vol 51 (2) ◽  
pp. 177-183 ◽  
Author(s):  
Mauro Silingardi ◽  
Carlo Salvarani ◽  
Luigi Boiardi ◽  
Pietro Accardo ◽  
Alfonso Iorio ◽  
...  

2001 ◽  
Vol 293 (10) ◽  
pp. 537-539 ◽  
Author(s):  
U. Tursen ◽  
T. I. Kaya ◽  
G. Eskandari ◽  
O. Gunduz ◽  
M. Yazar ◽  
...  

2003 ◽  
Vol 33 (3) ◽  
pp. 157-163 ◽  
Author(s):  
Aşkın Ateş ◽  
Nurşen Düzgün ◽  
Arzu Ulu ◽  
A. Olcay Aydintuğ Tiryaki ◽  
Nejat Akar

2006 ◽  
Vol 95 (04) ◽  
pp. 618-624 ◽  
Author(s):  
José Ricart ◽  
José Todolí ◽  
Javier Calvo ◽  
Piedad Villa ◽  
Amparo Estellés ◽  
...  

SummaryBehçet’s disease (BD) is a chronic inflammatory disorder in which thrombosis occurs in about 30% of patients. The prothrombotic mechanisms are unknown. Thrombophilic defects and hyperhomocysteinaemia may be involved in the pathogenesis of thrombotic events, although results have been controversial. Moreover, no information is available on this issue for eastern Spain.We studied the prevalence of inherited and acquired thrombophilic risk factors in 79 patients with BD (43 men, 36 women) who had (n = 23) or did not have (n = 56) thrombosis, and in 84 healthy control subjects (42 men, 42 women). Risk factors examined were antithrombin, protein C and protein S levels, factor V Leiden, the prothrombin G20210A mutation, the methylenetetrahydrofolate reductase C677T polymorphism, and acquired thrombophilic risk factors, including anticardiolipin antibodies, lupus anticoagulant, and serum homocysteine levels. There were no differences between patients and controls in any of the parameters studied.When we studied BD patients with and without thrombotic events, the only thrombophilic defect that differed was the prothrombin G20210A mutation: Three out of 23 patients with thrombosis were carriers, compared with none of 56 patients without thrombosis (p = 0.022).Two of the three carriers developed catastrophic or recurrent thrombotic episodes; one wasa homozygous carrier of the G20210A prothrombin mutation and the other was doubly heterozygous for the G20210A prothrombin mutation and factor V Leiden. A meta-analysis demonstrated an association of factor V Leiden and prothrombin mutation with thrombosis in BD. When studies from Turkey were excluded from the meta-analysis, only the prothrombin G20210A mutation was associated with thrombosis.


1991 ◽  
Vol 66 (03) ◽  
pp. 292-294 ◽  
Author(s):  
K K Hampton ◽  
M A Chamberlain ◽  
D K Menon ◽  
J A Davies

SummaryCoagulation and fibrinolytic activities were studied in 18 subjects with Behçet's disease and compared with results from 14 matched control patients suffering from sero-negative arthritis. Significantly higher plasma concentrations (median and range) were found in Behçet's patients for the following variables: fibrinogen 3.7 (1.7-6.9) vs 3.0 (2.0-5.1) g/1, p <0.05; von Willebrand factor antigen, 115 (72-344) vs 74 (60-119)%, p <0.002; plasminogen activator activity (106/ECLT2) 219 (94-329) vs 137 (78-197) units, p <0.002; tissue plasminogen activator inhibitor (t-PA-I) activity, 9.1 (5.5-19.3) vs 5.1 (1.8-12.0) IU/ml, p <0.002; and PAI-1 antigen, 13.9 (4.5-20.9) vs 6.4 (2.4-11.1) ng/ml, p <0.002. Protein C antigen was significantly lower: 97 (70-183) vs 126 (96-220)%, p <0.02. No differences were observed in antithrombin III activity or antigen, factor VIII coagulant activity, fibrinopeptides A and Bβ15-42, plasminogen, α-2-antiplasmin, functional and immunological tissue-plasminogen activator, thrombin-antithrombin complexes and D-dimer. Levels of tissue plasminogen activator inhibitor (activity and antigen) correlated with disease activity while fibrinogen and von Willebrand factor concentrations did not. Seven of the 18 subjects with Behçet's disease had suffered thrombotic events but it was not possible to distinguish these from the 11 patients without thrombosis using the assays performed. The results suggest the abnormal fibrinolytic activity in Behçet's disease is due to increased inhibition of tissue plasminogen activator. No abnormality of coagulation or fibrinolytic activity specific to Behçet's disease was detected.


1996 ◽  
Vol 75 (06) ◽  
pp. 974-975 ◽  
Author(s):  
İbrahim C Haznedaroğlu ◽  
Oktay Özdemir ◽  
Osman Özcebe ◽  
Semra V Dündar ◽  
Şerafettin Kirazli

Sign in / Sign up

Export Citation Format

Share Document